scholarly journals ALLERGIC RHINITIS AND IMPORTANCE OF FEXOFENADINE HCL SUSTAINED RELEASE MICROSPHERE AS ITS TREATMENT APPROACH

2022 ◽  
pp. 13-17
Author(s):  
PAROMA AREFIN ◽  
MD SHEHAN HABIB ◽  
NAZIM UDDIN AHMED ◽  
MD ABDUR RAHIM ◽  
MD IBRAHIM ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Sustained Release ◽  
Half Life ◽  
Immediate Release ◽  
Current Treatment ◽  
Treatment Approaches ◽  
Antihistamine Drug ◽  
Fexofenadine Hcl ◽  
Red Eyes

The current treatment approaches for allergic rhinitis are practiced over decades, but the patient quality of life has not yet changed so much. The reasons are research gaps in pathophysiology of the disease, proper management of the disease. Fexofenadine HCl is a second-generation antihistamine drug which has a half-life of about 14.4 h. It is useful in the management of common symptoms like sneezing, itchy throat, and red eyes in individuals suffering from allergic rhinitis. Fexofenadine immediate release or sustained release formulations are available in the market as suspension, tablet and capsule. In this research paper, we have discussed the symptoms associated with allergic rhinitis and treatment approaches. Fexofenadine HCl is being used for the treatment of this disease. But as it has a long half-life, we have discussed the importance of the introduction of sustained-release microsphere formulation of Fexofenadine HCl in the market.

scholarly journals THE ROLE OF MODERN ANTIHISTAMINES IN THE TREATMENT OF ALLERGIC DISEASES

2017 ◽  
Vol 14 (4-5) ◽  
pp. 80-88
Author(s):  
N M Nenasheva
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Second Generation ◽  
Allergic Diseases ◽  
Pharmaceutical Market ◽  
Common Diseases ◽  
First Choice ◽  
Antihistamine Drug

Allergic rhinitis and urticaria - are common diseases which influence on the quality of life of patients reducing day activity and educability. The second generation of antihistamines are the first choice in the treatment of these diseases. At Russian pharmaceutical market a few dozens of different preparations of this group are available. Most of them are generic forms. The purpose of this article is to show the place of modern antihistamines in allergic rhinitis and urticaria therapy and to find out the best equivalent of generic antihistamine drug in comparison with the original one.

scholarly journals Fexofenadine HCl Microspheres – Can it be the First Line therapy for Allergic Disorders ?

2021 ◽  
Vol 18 (4) ◽  
pp. 795-799
Author(s):  
Paroma Arefin ◽  
Md Shehan Habib ◽  
Mohammad Mostafa ◽  
Dipankar Chakraborty ◽  
reebash Chandra Bhattacharjee ◽  
...  
Keyword(s):  
Treatment Options ◽  
Current Treatment ◽  
Allergen Specific Immunotherapy ◽  
Intranasal Corticosteroids ◽  
First Line Therapy ◽  
Current Therapies ◽  
Treatment Alternatives ◽  
Allergic Disorders ◽  
Fexofenadine Hcl

Fexofenadine HCl is a second-generation antihistamine which is commonly used for allergic disorders. But it has low bioavailability. Intranasal corticosteroids (INCs) and Immunotherapy and Allergen Specific Immunotherapy (ASIT) are now commonly being suggested for the treatment of allergic disorders. Despite the fact that current treatment alternatives have been in use for decades, patient quality of life has remained static. The treatment options are not much explored for their respective adverse effects. Therefore, they are in desperate need of research. Fexofenadine HCl is available in the form of a suspension, tablet, or capsule. In our current study, we have explored whether microspheres can be the perfect dosage form of Fexofenadine HCl to treat allergic disorders considering the pharmacokinetics of the drug, available dosage forms options and the probable side effects of the current therapies.

The improved factor concentrate

2009 ◽  
Vol 29 (01) ◽  
pp. 71-73 ◽  
Author(s):  
D. Lillicrap
Keyword(s):  
Quality Of Care ◽  
Replacement Therapy ◽  
Half Life ◽  
Biological Properties ◽  
Current Treatment ◽  
Coagulation Protein ◽  
Widespread Availability ◽  
The Cost ◽  
Factor Concentrate

SummaryThe current treatment of haemophilia with coagulation protein replacement therapy is both effective and safe. Nevertheless, this therapy requires frequent, repeated intravenous infusions and approximately 25% of treated haemo philia A patients develop antibodies to the replacement protein. Furthermore, the cost and limited availability of current concentrates has restricted access to therapy to less than 30% of the global haemophilia population. With this background, efforts are now underway to develop coagulation concentrates with enhanced biological properties that further improve the quality of care for haemophiliacs. The specific areas of enhancement that are being explored include improved biosynthetic processes, prolonging the circulating half-life and reducing concentrate immuno -genicity. Coincident with these approaches, it is hoped that there will be more widespread availability of these concentrates and that their cost will be contained.

Sleepiness, Quality of Life and Objective Sleep Patterns in Seasonal Allergic Rhinitis

2006 ◽  
Vol 18 (03) ◽  
pp. 120-126
Author(s):  
Boris Stuck ◽  
Karl Hörmann ◽  
Joachim Maurer ◽  
Anna-Eva Hagner ◽  
Julia Johnson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Sleep Patterns

NEUROENDOCRINE TUMORS OF THE PANCREAS: ETIOLOGY, PATHOGENESIS, DIAGNOSIS, AND CURRENT TREATMENT APPROACHES

2018 ◽  
Vol 64 (6) ◽  
pp. 830-839
Author(s):  
Temuri Morgoshiya
Keyword(s):  
Neuroendocrine Tumors ◽  
Clinical Manifestations ◽  
Gastrointestinal Hormones ◽  
Current Treatment ◽  
High Potential ◽  
Long Term Results ◽  
Considerable Part ◽  
Treatment Approaches ◽  
By Products

The overview of literature on modem classification issues, diagnostics and treatments of neuroendocrinal tumors of a pancreas is provided. According to modern views all neuroendocrinal tumors of a pancreas having clinical manifestations (in the form of the syndromes caused by products of specific hormones; increases in level of hormones in blood of patients without clinical manifestations; in the form of signs of existence of volume education in various departments of PZh) and/or the researches (more than 5 mm) revealed by means of beam methods are malignant in the biology as they have high potential to innidiation. In article it is shown that a considerable part of neuroendocrinal tumors of a pancreas are nonfunctioning, i.e. not cosecreting various gastrointestinal hormones and polypeptides in blood and thereof not followed characteristic clinical manifestations. It is noted that diagnostics of neuroendocrinal tumors of a pancreas is extremely difficult task on which solution the choice of a method of treatment and its long-term results depends...

Development and Characterization of LBG-PVA Interpenetrating Networks Incorporating Gliclazide for Sustained Release

2020 ◽  
Vol 15 ◽  
Author(s):  
Ashish Katoch ◽  
Manju Nagpal ◽  
Malkiet Kaur ◽  
Manjinder Singh ◽  
Geeta Aggarwal ◽  
...  
Keyword(s):  
Solid State ◽  
Sustained Release ◽  
Half Life ◽  
Solid State Nmr ◽  
Oral Dosage ◽  
Cross Linking ◽  
Interpenetrating Networks ◽  
Dsc Studies ◽  
Biological Half Life ◽  
Percentage Yield

Background: Controlled oral dosage forms have always been preferred for drugs with variable absorption, and short biological half life and frequent dosing. The prime goal with sustained release systems is to maintain uniform therapeutic blood levels for longer periods of time. Interpenetrating networks (IPNs) have been evidenced as uniform sustained release systems. In current study, polyvinyl alcohol (PVA) and locust bean gum (LBG) based IPNs were developed for the oral sustained release drug delivery of gliclazide (shows variable absorption). Method: The IPNs were synthesized by emulsion cross-linking method using glutaraldehyde (GA) as a cross linking agent. Gliclazide is a potential second generation, short-acting sulfonylurea oral hypoglycemic agent is having a short biological half-life (2-4 h), variable absorption and poor oral bioavailability. Various batches of IPNs were formulated by varying LBG: PVA ratio and evaluated for percentage yield, drug entrapment efficiency (DEE), swelling properties and in vitro drug release studies. Further characterizations were done by Fourier Transform Infrared Spectroscopy (FTIR), C13 Solid state NMR, X-Ray diffraction study (XRD), Scanning electron microscopy (SEM), and Differential scanning microscopy (DSC) studies. Results: The percentage yield, drug entrapment and equilibrium swelling was observed to be dependent on PVA-LBG ratio and GA amount. Sustained release of drug was observed in all IPN formulations (approx 59 - 86% in 8 h in various batches) with variable release kinetics. SEM studies revealed the regular structures of IPNs. FTIR, XRD, C13 Solid state NMR and DSC studies proposed that drug was successfully incorporated into the formed IPNs. Conclusion: IPNs of LBG and PVA can be used as a promising carrier with uniform sustained release characteristics.

Sign in / Sign up

Export Citation Format

Share Document